Following on from information provided to NICE by the company in February 2019, the appraisal of Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1458 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2019, the appraisal of Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 December 2019 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Following on from an update received from company that they are no longer pursuing a Marketing Authorisation Application to the European Medicines Agency at this time, this appraisal remains suspended. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 29 March 2019 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Following on from advice received from the company NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 28 September 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late April 2019. |
| 15 August 2018 - 13 September 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 21 March 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual